Xiaofeng A. Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xiaofeng A. Su has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Kathryn L. Penney
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
7 shared publications - Konrad H. Stopsack
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
7 shared publications - Andreas Pettersson
Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
6 shared publications - Ericka M. Ebot
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
6 shared publications - J. Bailey Vaselkiv
Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, MA
6 shared publications - Lorelei A. Mucci
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
6 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Springer Nature in Cell Death & Differentiation
- p. 1-15
SMARCA5 facilitates cohesin localization at R-loops to prevent transcription-replication collisions
The cohesin complex is well recognized for maintaining sister chromatid cohesion during mitosis and meiosis, as well as for its role in genome organization through chromatin loop formation. Recent studies indicate that cohesin can be co-opted in cancer by aiding DNA repair processes to promote cancer cell proliferation. However, the mechanisms, protein partners, and functions by which cohesin is involved in DNA repair remain unclear. Here, we uncover a novel function of cohesin core subunits (RAD21, STAG1/2) in promoting transcription-coupled homologous recombination (TC-HR) at sites of R-loops. We demonstrate that cohesin (SMC1/3, RAD21, STAG1) preferentially localizes to R-loops in vitro and localize to DNA damage-induced R-loops in cells. Through a screen of chromatin remodelers, we identify that chromatin remodeler SMARCA5 recruits RAD21 and STAG at R-loop sites. SMARCA5 forms a complex with RAD21 via its SLIDE domain and is recruited to R-loops, providing a dual mechanism to promote the R-loop localization of the cohesin core subunits. The ATPase activity of SMARCA5 facilitates the localization of RAD21 and RAD51 at sites of R-loops to promote TC-HR and timely resolution of R-loops. Depletion of either core subunits of cohesin or SMARCA5, both of which are overexpressed in a subset of cancers, leads to aberrant R-loop accumulation, stalled replication fork progression, and elevated transcription-replication collision (TRC) events induced cell death. These findings shed new light on a previously unknown function of SMARCA5 through regulating cohesin core subunits RAD21/STAG at R-loops and established their potential as therapeutic targets in treating cancer.
- 28 October 2026
- Published by Springer Nature in Cell Death & Differentiation
- p. 1-15
Open AccessSMARCA5 facilitates cohesin localization at R-loops to prevent transcription-replication collisions
The cohesin complex is well recognized for maintaining sister chromatid cohesion during mitosis and meiosis, as well as for its role in genome organization through chromatin loop formation. Recent studies indicate that cohesin can be co-opted in cancer by aiding DNA repair processes to promote cancer cell proliferation. However, the mechanisms, protein partners, and functions by which cohesin is involved in DNA repair remain unclear. Here, we uncover a novel function of cohesin core subunits (RAD21, STAG1/2) in promoting transcription-coupled homologous recombination (TC-HR) at sites of R-loops. We demonstrate that cohesin (SMC1/3, RAD21, STAG1) preferentially localizes to R-loops in vitro and localize to DNA damage-induced R-loops in cells. Through a screen of chromatin remodelers, we identify that chromatin remodeler SMARCA5 recruits RAD21 and STAG at R-loop sites. SMARCA5 forms a complex with RAD21 via its SLIDE domain and is recruited to R-loops, providing a dual mechanism to promote the R-loop localization of the cohesin core subunits. The ATPase activity of SMARCA5 facilitates the localization of RAD21 and RAD51 at sites of R-loops to promote TC-HR and timely resolution of R-loops. Depletion of either core subunits of cohesin or SMARCA5, both of which are overexpressed in a subset of cancers, leads to aberrant R-loop accumulation, stalled replication fork progression, and elevated transcription-replication collision (TRC) events induced cell death. These findings shed new light on a previously unknown function of SMARCA5 through regulating cohesin core subunits RAD21/STAG at R-loops and established their potential as therapeutic targets in treating cancer.
- Open Access
Streamline CNV – A Handy Nextflow Pipeline for Chromosomal Copy Number Variation Analysis
Background: Aneuploidy, characterized by imbalanced chromosomal copy number variation (CNV), occurs in both normal somatic tissues and a wide range of diseases. Low pass whole genome sequencing (LP-WGS) to detect CNVs in cells and tissues has been widely used in all biological research. Existing informatics tools for detecting CNV often require computational expertise, often posing challenges for wet-lab biologists. To address this need, we developed Streamline CNV (SLCNV) - a user-friendly and flexible copy number analysis pipeline that allows researchers to perform many copy number-related analyses steps with a single, straightforward command. Results: Streamline CNV is based on Nextflow and is packaged in a Docker image that can be executed using Singularity, making it portable and reproducible across different user environments. The pipeline automatically processes input data, performs sequencing quality control to filter problematic samples, outputs mapping statistics, CNV calling, and generates outputs including intuitive CNV plots, segmentation files (with statistics), annotation of genes on altered chromosomes, evaluation of proportion of chromosomal regions that are non-euploid. Based on user preferences, it can cluster samples solely based on CNV patterns, map the genomic location and density of genes of interest along chromosomes, and visually highlight regions with evident CNVs. In addition, it allows users to select and order chromosomes for display in plots, define sample label color palettes, and choose whether to include sample labels in the clustering visualizations. It also allows users to specify the amount of computing resources to allocate to the pipeline, such as CPU, memory, and runtime. Streamline CNV can be customizable and upgradable. It works with any species and genome assembly and efficiently supports both single-cell and bulk sequencing data with improved performance coding. Jobs can be distributed across cores of a basic Unix workstation, multiple nodes in a high-performance computing cluster using the Slurm scheduler, or cloud environments, as needed. Conclusions: We demonstrated the tool using an in-house sequencing dataset of human and mouse cell lines. Our results showed that the Streamline CNV pipeline effectively detected copy number patterns and generated informative summaries. It annotated the findings by identifying affected genes within the copy-number segments and at the break-end regions. It also reported the proportions of altered chromosomal regions impacted by copy number changes for each sample. The clustering plot demonstrated the relationships between samples based on their copy number profiles. Gene density plots aid in interpreting how genes from distinct pathways are associated with CNV pattern alterations. This tool enables researchers, regardless of bioinformatics expertise, to perform comprehensive CNV analyses across a wide range of scenarios. It also facilitates the interpretation of the copy number results and makes it possible for transforming raw CNV data into further exploration of meaningful biological insights.
Open AccessStreamline CNV – A Handy Nextflow Pipeline for Chromosomal Copy Number Variation Analysis
Background: Aneuploidy, characterized by imbalanced chromosomal copy number variation (CNV), occurs in both normal somatic tissues and a wide range of diseases. Low pass whole genome sequencing (LP-WGS) to detect CNVs in cells and tissues has been widely used in all biological research. Existing informatics tools for detecting CNV often require computational expertise, often posing challenges for wet-lab biologists. To address this need, we developed Streamline CNV (SLCNV) - a user-friendly and flexible copy number analysis pipeline that allows researchers to perform many copy number-related analyses steps with a single, straightforward command. Results: Streamline CNV is based on Nextflow and is packaged in a Docker image that can be executed using Singularity, making it portable and reproducible across different user environments. The pipeline automatically processes input data, performs sequencing quality control to filter problematic samples, outputs mapping statistics, CNV calling, and generates outputs including intuitive CNV plots, segmentation files (with statistics), annotation of genes on altered chromosomes, evaluation of proportion of chromosomal regions that are non-euploid. Based on user preferences, it can cluster samples solely based on CNV patterns, map the genomic location and density of genes of interest along chromosomes, and visually highlight regions with evident CNVs. In addition, it allows users to select and order chromosomes for display in plots, define sample label color palettes, and choose whether to include sample labels in the clustering visualizations. It also allows users to specify the amount of computing resources to allocate to the pipeline, such as CPU, memory, and runtime. Streamline CNV can be customizable and upgradable. It works with any species and genome assembly and efficiently supports both single-cell and bulk sequencing data with improved performance coding. Jobs can be distributed across cores of a basic Unix workstation, multiple nodes in a high-performance computing cluster using the Slurm scheduler, or cloud environments, as needed. Conclusions: We demonstrated the tool using an in-house sequencing dataset of human and mouse cell lines. Our results showed that the Streamline CNV pipeline effectively detected copy number patterns and generated informative summaries. It annotated the findings by identifying affected genes within the copy-number segments and at the break-end regions. It also reported the proportions of altered chromosomal regions impacted by copy number changes for each sample. The clustering plot demonstrated the relationships between samples based on their copy number profiles. Gene density plots aid in interpreting how genes from distinct pathways are associated with CNV pattern alterations. This tool enables researchers, regardless of bioinformatics expertise, to perform comprehensive CNV analyses across a wide range of scenarios. It also facilitates the interpretation of the copy number results and makes it possible for transforming raw CNV data into further exploration of meaningful biological insights.
- Open Access
- 28 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (35)
SpotMAX: A generalist framework for multidimensional automatic spot detection and quantification
The analysis of spot-like structures is a widespread task in microscopy image analysis. Existing solutions are typically specific to single applications and do not use multidimensional information, often leaving manual annotation as the only option. Here, we present SpotMAX, a generalist AI-assisted framework for automated spot detection and quantification. SpotMAX detects spots in three-dimensional (3D) data and leverages the full scope of multidimensional datasets with an easy-to-use graphical user interface and a framework for cell segmentation and tracking. Tested on a large 3D dataset, SpotMAX outperforms or is on par with state-of-the-art tools and expert human annotators. We applied SpotMAX across diverse experimental questions, ranging from meiotic crossover events in Caenorhabditis elegans to mitochondrial DNA dynamics in Saccharomyces cerevisiae and telomere length in mouse stem cells, leading to new biological insights. With its flexibility in integrating other AI models into a holistic analysis workflow, we anticipate that SpotMAX will become the standard for spot analysis in microscopy data.
- 28 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (35)
Open AccessSpotMAX: A generalist framework for multidimensional automatic spot detection and quantification
The analysis of spot-like structures is a widespread task in microscopy image analysis. Existing solutions are typically specific to single applications and do not use multidimensional information, often leaving manual annotation as the only option. Here, we present SpotMAX, a generalist AI-assisted framework for automated spot detection and quantification. SpotMAX detects spots in three-dimensional (3D) data and leverages the full scope of multidimensional datasets with an easy-to-use graphical user interface and a framework for cell segmentation and tracking. Tested on a large 3D dataset, SpotMAX outperforms or is on par with state-of-the-art tools and expert human annotators. We applied SpotMAX across diverse experimental questions, ranging from meiotic crossover events in Caenorhabditis elegans to mitochondrial DNA dynamics in Saccharomyces cerevisiae and telomere length in mouse stem cells, leading to new biological insights. With its flexibility in integrating other AI models into a holistic analysis workflow, we anticipate that SpotMAX will become the standard for spot analysis in microscopy data.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-5, Supplementary Figures 1-3 from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
Table S1. ETS genes with weaker evidence for association with ERG fusion status. Table S2. Androgen receptor transcriptional activity, measured as a más-o-menos score of the Hiernonymus et al. (2006) signature and expressed in standard deviations within a cohort, between ETS-defined subtypes, in TCGA and the Hopkins cohort. Table S3. All genes associated with ERG vs. non-ERG status among the Berglund et al. ETS genes, sorted by increasing p-value in HPFS/PHS. Missing estimates for the validation cohorts (HPFS/PHS and Hopkins) indicate the gene was not measured on the microarrays used in these studies. Table S4. Ratios between Black and White men for ratios of expression between ETS vs. non-ETS tumors. Table S5. Gene set analysis for Hallmark gene sets associated with ERG vs. non-ERG (top), ETS vs. non-ETS (middle), and non-ERG ETS vs. non-ETS status (bottom). Figure S1. Gene expression ratios in TCGA for ETS vs. non-SPOP non-ETS (x axis) and ETS vs. SPOP non-ETS (y-axis). One dot is one tumor. Figure S2. Androgen receptor transcriptional activity by subtype. One dot is one tumor. Figure S3. ETS-related AR target genes.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-5, Supplementary Figures 1-3 from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
Table S1. ETS genes with weaker evidence for association with ERG fusion status. Table S2. Androgen receptor transcriptional activity, measured as a más-o-menos score of the Hiernonymus et al. (2006) signature and expressed in standard deviations within a cohort, between ETS-defined subtypes, in TCGA and the Hopkins cohort. Table S3. All genes associated with ERG vs. non-ERG status among the Berglund et al. ETS genes, sorted by increasing p-value in HPFS/PHS. Missing estimates for the validation cohorts (HPFS/PHS and Hopkins) indicate the gene was not measured on the microarrays used in these studies. Table S4. Ratios between Black and White men for ratios of expression between ETS vs. non-ETS tumors. Table S5. Gene set analysis for Hallmark gene sets associated with ERG vs. non-ERG (top), ETS vs. non-ETS (middle), and non-ERG ETS vs. non-ETS status (bottom). Figure S1. Gene expression ratios in TCGA for ETS vs. non-SPOP non-ETS (x axis) and ETS vs. SPOP non-ETS (y-axis). One dot is one tumor. Figure S2. Androgen receptor transcriptional activity by subtype. One dot is one tumor. Figure S3. ETS-related AR target genes.
- Open Access
- 19 November 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (2)
Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice
Phenotypic plasticity is a hallmark of cancer and is increasingly realized as a mechanism of resistance to androgen receptor–targeted (AR-targeted) therapy. Now that many prostate cancer (PCa) patients are treated upfront with AR-targeted agents, it is critical to identify actionable mechanisms that drive phenotypic plasticity, to prevent the emergence of resistance. We showed that loss of tristetraprolin (TTP; gene ZFP36 ) increased NF-κB activation, and was associated with higher rates of aggressive disease and early recurrence in primary PCa. We also examined the clinical and biological impact of ZFP36 loss with co-loss of PTEN , a known driver of PCa. Analysis of multiple independent primary PCa cohorts demonstrated that PTEN and ZFP36 co-loss was associated with increased recurrence risk. Engineering prostate-specific Zfp36 deletion in vivo induced prostatic intraepithelial neoplasia, and, with Pten codeletion, resulted in rapid progression to castration-resistant adenocarcinoma. Zfp36 loss altered the cell state driven by Pten loss, as demonstrated by enrichment of epithelial–mesenchymal transition (EMT), inflammation, TNF-α/NF-κB, and IL-6–JAK/STAT3 gene sets. Additionally, our work revealed that ZFP36 loss also induced enrichment of multiple gene sets involved in mononuclear cell migration, chemotaxis, and proliferation. Use of the NF-κB inhibitor dimethylaminoparthenolide (DMAPT) induced marked therapeutic responses in tumors with PTEN and ZFP36 co-loss and reversed castration resistance.
- 19 November 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (2)
Open AccessLow tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice
Phenotypic plasticity is a hallmark of cancer and is increasingly realized as a mechanism of resistance to androgen receptor–targeted (AR-targeted) therapy. Now that many prostate cancer (PCa) patients are treated upfront with AR-targeted agents, it is critical to identify actionable mechanisms that drive phenotypic plasticity, to prevent the emergence of resistance. We showed that loss of tristetraprolin (TTP; gene ZFP36 ) increased NF-κB activation, and was associated with higher rates of aggressive disease and early recurrence in primary PCa. We also examined the clinical and biological impact of ZFP36 loss with co-loss of PTEN , a known driver of PCa. Analysis of multiple independent primary PCa cohorts demonstrated that PTEN and ZFP36 co-loss was associated with increased recurrence risk. Engineering prostate-specific Zfp36 deletion in vivo induced prostatic intraepithelial neoplasia, and, with Pten codeletion, resulted in rapid progression to castration-resistant adenocarcinoma. Zfp36 loss altered the cell state driven by Pten loss, as demonstrated by enrichment of epithelial–mesenchymal transition (EMT), inflammation, TNF-α/NF-κB, and IL-6–JAK/STAT3 gene sets. Additionally, our work revealed that ZFP36 loss also induced enrichment of multiple gene sets involved in mononuclear cell migration, chemotaxis, and proliferation. Use of the NF-κB inhibitor dimethylaminoparthenolide (DMAPT) induced marked therapeutic responses in tumors with PTEN and ZFP36 co-loss and reversed castration resistance.
- Open Access
SpotMAX: a generalist framework for multi-dimensional automatic spot detection and quantification
The analysis of spot-like structures is a widespread task in microscopy-based cell biology. Existing solutions are typically specific to single applications and do not use multi-dimensional information from 5D datasets. Therefore, experimental scientists often resort to subjective manual annotation. Here, we present SpotMAX, a generalist AI-driven framework for automated spot detection and quantification. SpotMAX leverages the full scope of multi-dimensional datasets with an easy-to-use interface and an embedded framework for cell segmentation and tracking. SpotMAX outperforms state-of-the-art tools, and in some cases, even expert human annotators. We applied SpotMAX across diverse experimental questions, ranging from meiotic crossover events in C. elegans to mitochondrial DNA dynamics in S. cerevisiae and telomere length in mouse stem cells, leading to new biological insights. With its flexibility in integrating AI workflows, we anticipate that SpotMAX will become the standard for spot analysis in microscopy data. Source code: https://github.com/SchmollerLab/SpotMAX
Open AccessSpotMAX: a generalist framework for multi-dimensional automatic spot detection and quantification
The analysis of spot-like structures is a widespread task in microscopy-based cell biology. Existing solutions are typically specific to single applications and do not use multi-dimensional information from 5D datasets. Therefore, experimental scientists often resort to subjective manual annotation. Here, we present SpotMAX, a generalist AI-driven framework for automated spot detection and quantification. SpotMAX leverages the full scope of multi-dimensional datasets with an easy-to-use interface and an embedded framework for cell segmentation and tracking. SpotMAX outperforms state-of-the-art tools, and in some cases, even expert human annotators. We applied SpotMAX across diverse experimental questions, ranging from meiotic crossover events in C. elegans to mitochondrial DNA dynamics in S. cerevisiae and telomere length in mouse stem cells, leading to new biological insights. With its flexibility in integrating AI workflows, we anticipate that SpotMAX will become the standard for spot analysis in microscopy data. Source code: https://github.com/SchmollerLab/SpotMAX
- Open Access
- 27 August 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (36)
RAD21 promotes oncogenesis and lethal progression of prostate cancer
Higher levels of aneuploidy, characterized by imbalanced chromosome numbers, are associated with lethal progression in prostate cancer. However, how aneuploidy contributes to prostate cancer aggressiveness remains poorly understood. In this study, we assessed in patients which genes on chromosome 8q, one of the most frequently gained chromosome arms in prostate tumors, were most strongly associated with long-term risk of cancer progression to metastases and death from prostate cancer (lethal disease) in 403 patients and found the strongest candidate was cohesin subunit gene, RAD21 , with an odds ratio of 3.7 (95% CI 1.8, 7.6) comparing the highest vs. lowest tertiles of mRNA expression and adjusting for overall aneuploidy burden and Gleason score, both strong prognostic factors in primary prostate cancer. Studying prostate cancer driven by the TMPRSS2-ERG oncogenic fusion, found in about half of all prostate tumors, we found that increased RAD21 alleviated toxic oncogenic stress and DNA damage caused by oncogene expression. Data from both organoids and patients indicate that increased RAD21 thereby enables aggressive tumors to sustain tumor proliferation, and more broadly suggests one path through which tumors benefit from aneuploidy.
- 27 August 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (36)
Open AccessRAD21 promotes oncogenesis and lethal progression of prostate cancer
Higher levels of aneuploidy, characterized by imbalanced chromosome numbers, are associated with lethal progression in prostate cancer. However, how aneuploidy contributes to prostate cancer aggressiveness remains poorly understood. In this study, we assessed in patients which genes on chromosome 8q, one of the most frequently gained chromosome arms in prostate tumors, were most strongly associated with long-term risk of cancer progression to metastases and death from prostate cancer (lethal disease) in 403 patients and found the strongest candidate was cohesin subunit gene, RAD21 , with an odds ratio of 3.7 (95% CI 1.8, 7.6) comparing the highest vs. lowest tertiles of mRNA expression and adjusting for overall aneuploidy burden and Gleason score, both strong prognostic factors in primary prostate cancer. Studying prostate cancer driven by the TMPRSS2-ERG oncogenic fusion, found in about half of all prostate tumors, we found that increased RAD21 alleviated toxic oncogenic stress and DNA damage caused by oncogene expression. Data from both organoids and patients indicate that increased RAD21 thereby enables aggressive tumors to sustain tumor proliferation, and more broadly suggests one path through which tumors benefit from aneuploidy.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
The most common somatic event in primary prostate cancer is a fusion between the androgen-related TMPRSS2 gene and the ERG oncogene. Tumors with these fusions, which occur early in carcinogenesis, have a distinctive etiology. A smaller subset of other tumors harbor fusions between TMPRSS2 and members of the ETS transcription factor family other than ERG. To assess the genomic similarity of tumors with non-ERG ETS fusions and those with fusions involving ERG, this study derived a transcriptomic signature of non-ERG ETS fusions and assessed this signature and ERG-related gene expression in 1,050 men with primary prostate cancer from three independent population-based and hospital-based studies. Although non-ERG ETS fusions involving ETV1, ETV4, ETV5, or FLI1 were individually rare, they jointly accounted for one in seven prostate tumors. Genes differentially regulated between non-ERG ETS tumors and tumors without ETS fusions showed similar differential expression when ERG tumors and tumors without ETS fusions were compared (differences explained: R2 = 69–77%), including ETS-related androgen receptor (AR) target genes. Differences appeared to result from similarities among ETS tumors rather than similarities among non-ETS tumors. Gene sets associated with ERG fusions were consistent with gene sets associated with non-ERG ETS fusions, including fatty acid and amino acid metabolism, an observation that was robust across cohorts.Implications:Considering ETS fusions jointly may be useful for etiologic studies on prostate cancer, given that the transcriptome is profoundly impacted by ERG and non-ERG ETS fusions in a largely similar fashion, most notably genes regulating metabolic pathways.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
The most common somatic event in primary prostate cancer is a fusion between the androgen-related TMPRSS2 gene and the ERG oncogene. Tumors with these fusions, which occur early in carcinogenesis, have a distinctive etiology. A smaller subset of other tumors harbor fusions between TMPRSS2 and members of the ETS transcription factor family other than ERG. To assess the genomic similarity of tumors with non-ERG ETS fusions and those with fusions involving ERG, this study derived a transcriptomic signature of non-ERG ETS fusions and assessed this signature and ERG-related gene expression in 1,050 men with primary prostate cancer from three independent population-based and hospital-based studies. Although non-ERG ETS fusions involving ETV1, ETV4, ETV5, or FLI1 were individually rare, they jointly accounted for one in seven prostate tumors. Genes differentially regulated between non-ERG ETS tumors and tumors without ETS fusions showed similar differential expression when ERG tumors and tumors without ETS fusions were compared (differences explained: R2 = 69–77%), including ETS-related androgen receptor (AR) target genes. Differences appeared to result from similarities among ETS tumors rather than similarities among non-ETS tumors. Gene sets associated with ERG fusions were consistent with gene sets associated with non-ERG ETS fusions, including fatty acid and amino acid metabolism, an observation that was robust across cohorts.Implications:Considering ETS fusions jointly may be useful for etiologic studies on prostate cancer, given that the transcriptome is profoundly impacted by ERG and non-ERG ETS fusions in a largely similar fashion, most notably genes regulating metabolic pathways.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
The most common somatic event in primary prostate cancer is a fusion between the androgen-related TMPRSS2 gene and the ERG oncogene. Tumors with these fusions, which occur early in carcinogenesis, have a distinctive etiology. A smaller subset of other tumors harbor fusions between TMPRSS2 and members of the ETS transcription factor family other than ERG. To assess the genomic similarity of tumors with non-ERG ETS fusions and those with fusions involving ERG, this study derived a transcriptomic signature of non-ERG ETS fusions and assessed this signature and ERG-related gene expression in 1,050 men with primary prostate cancer from three independent population-based and hospital-based studies. Although non-ERG ETS fusions involving ETV1, ETV4, ETV5, or FLI1 were individually rare, they jointly accounted for one in seven prostate tumors. Genes differentially regulated between non-ERG ETS tumors and tumors without ETS fusions showed similar differential expression when ERG tumors and tumors without ETS fusions were compared (differences explained: R2 = 69–77%), including ETS-related androgen receptor (AR) target genes. Differences appeared to result from similarities among ETS tumors rather than similarities among non-ETS tumors. Gene sets associated with ERG fusions were consistent with gene sets associated with non-ERG ETS fusions, including fatty acid and amino acid metabolism, an observation that was robust across cohorts.Implications:Considering ETS fusions jointly may be useful for etiologic studies on prostate cancer, given that the transcriptome is profoundly impacted by ERG and non-ERG ETS fusions in a largely similar fashion, most notably genes regulating metabolic pathways.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
The most common somatic event in primary prostate cancer is a fusion between the androgen-related TMPRSS2 gene and the ERG oncogene. Tumors with these fusions, which occur early in carcinogenesis, have a distinctive etiology. A smaller subset of other tumors harbor fusions between TMPRSS2 and members of the ETS transcription factor family other than ERG. To assess the genomic similarity of tumors with non-ERG ETS fusions and those with fusions involving ERG, this study derived a transcriptomic signature of non-ERG ETS fusions and assessed this signature and ERG-related gene expression in 1,050 men with primary prostate cancer from three independent population-based and hospital-based studies. Although non-ERG ETS fusions involving ETV1, ETV4, ETV5, or FLI1 were individually rare, they jointly accounted for one in seven prostate tumors. Genes differentially regulated between non-ERG ETS tumors and tumors without ETS fusions showed similar differential expression when ERG tumors and tumors without ETS fusions were compared (differences explained: R2 = 69–77%), including ETS-related androgen receptor (AR) target genes. Differences appeared to result from similarities among ETS tumors rather than similarities among non-ETS tumors. Gene sets associated with ERG fusions were consistent with gene sets associated with non-ERG ETS fusions, including fatty acid and amino acid metabolism, an observation that was robust across cohorts.Implications:Considering ETS fusions jointly may be useful for etiologic studies on prostate cancer, given that the transcriptome is profoundly impacted by ERG and non-ERG ETS fusions in a largely similar fashion, most notably genes regulating metabolic pathways.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-5, Supplementary Figures 1-3 from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
Table S1. ETS genes with weaker evidence for association with ERG fusion status. Table S2. Androgen receptor transcriptional activity, measured as a más-o-menos score of the Hiernonymus et al. (2006) signature and expressed in standard deviations within a cohort, between ETS-defined subtypes, in TCGA and the Hopkins cohort. Table S3. All genes associated with ERG vs. non-ERG status among the Berglund et al. ETS genes, sorted by increasing p-value in HPFS/PHS. Missing estimates for the validation cohorts (HPFS/PHS and Hopkins) indicate the gene was not measured on the microarrays used in these studies. Table S4. Ratios between Black and White men for ratios of expression between ETS vs. non-ETS tumors. Table S5. Gene set analysis for Hallmark gene sets associated with ERG vs. non-ERG (top), ETS vs. non-ETS (middle), and non-ERG ETS vs. non-ETS status (bottom). Figure S1. Gene expression ratios in TCGA for ETS vs. non-SPOP non-ETS (x axis) and ETS vs. SPOP non-ETS (y-axis). One dot is one tumor. Figure S2. Androgen receptor transcriptional activity by subtype. One dot is one tumor. Figure S3. ETS-related AR target genes.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-5, Supplementary Figures 1-3 from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
Table S1. ETS genes with weaker evidence for association with ERG fusion status. Table S2. Androgen receptor transcriptional activity, measured as a más-o-menos score of the Hiernonymus et al. (2006) signature and expressed in standard deviations within a cohort, between ETS-defined subtypes, in TCGA and the Hopkins cohort. Table S3. All genes associated with ERG vs. non-ERG status among the Berglund et al. ETS genes, sorted by increasing p-value in HPFS/PHS. Missing estimates for the validation cohorts (HPFS/PHS and Hopkins) indicate the gene was not measured on the microarrays used in these studies. Table S4. Ratios between Black and White men for ratios of expression between ETS vs. non-ETS tumors. Table S5. Gene set analysis for Hallmark gene sets associated with ERG vs. non-ERG (top), ETS vs. non-ETS (middle), and non-ERG ETS vs. non-ETS status (bottom). Figure S1. Gene expression ratios in TCGA for ETS vs. non-SPOP non-ETS (x axis) and ETS vs. SPOP non-ETS (y-axis). One dot is one tumor. Figure S2. Androgen receptor transcriptional activity by subtype. One dot is one tumor. Figure S3. ETS-related AR target genes.